Subscribe

Subscribe to Our Newsletter

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks
Biotech Tech in Singapore

Singaporean therapy firm Tessa Therapeutics raises $126 million in Series A round

Oluwajuwonlo Afolabi profile image
by Oluwajuwonlo Afolabi
Updated
Singaporean therapy firm Tessa Therapeutics raises $126 million in Series A round
Photo by National Cancer Institute / Unsplash

Tessa Therapeutics, a therapy firm based in Singapore has raised $126 million in its Series A round to support the development of immune cell therapies for cancer.

  • The funds will help the firm to scale its cancer therapy development including the clinical trial of the TT11 programme and TT11x programme.
  • Founded in 2012, Tessa is a biotechnology firm focusing on CAR-T therapy, the harvesting of the immune cells in a patient, engineered to focus on cancer cells and infused in the patient.
  • The firm has a recorded around 57% complete response or disappearance of cancer cells in its TT11 ongoing phase 2 trial and complete disappearance of tumours in 4 out 9 cancer patients in its TT11x phase 1 study.
  • Polaris Partners led the funding round with participation from Temasek, EDBI, Heliconia Capital, and Heritas Capital.
Oluwajuwonlo Afolabi profile image
by Oluwajuwonlo Afolabi
Updated

Subscribe to Techloy.com

Get the latest information about companies, products, careers, and funding in the technology industry across emerging markets globally.

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks

Read More